dr. H.H.W. (Herman) Sillje
Herman Silljé obtained his Ph.D. in biotechnology at the University of Utrecht in the Netherlands. He completed a postdoctoral fellowship at the University of Geneva in Switzerland, and worked as a group leader at the Max Planck Institute for Biochemistry in Germany. He was scientific director of Kiadis Pharma, a biopharmaceutical company focused on cell-based immunotherapy. Recently, Sanofi completed the acquisition of Kiadis for 217 million euro. During the past 10 years Dr. Silljé has been the head of the preclinical experimental cardiology laboratory at the UMCG in Groningen and he is also principal investigator in the division of experimental cardiology at the UMCG. Dr. Silljé has authored and co-authored over 100 articles in peer reviewed journals.
|Last modified:||25 June 2022 02.54 a.m.|